Skip to main content

Advertisement

SpringerLink
Log in

Effect of the anti-retroviral drug, rilpivirine, on human subcutaneous adipose cells and its nutritional management using quercetin

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Rilpivirine, a recently developed drug of choice for initial treatment of HIV-1 infection, can greatly reduce HIV-related inflammation, but in turn, may be associated with adverse secondary effects, including disturbances in lipid metabolism and ultimately in adipose tissue distribution and function. In recent years, research findings on the benefits of anti-oxidant foods and supplements have been employed in counter-acting both oxidative stress as well as inflammation in order to reduce the adverse side effects of anti-retroviral therapy. One such natural flavonoid which possesses anti-inflammatory and anti-oxidative properties is quercetin. This study investigated the effect of quercetin in overcoming the side effects incurred due to rilpivirine administration. The results show substantial reduction in the accumulation of triglyceride levels in a dose- and time-dependent manner for adipose cells treated with either rilpivirine or quercetin alone and in combination, as evidenced by morphological pictures and quantitative measurement of triglycerides throughout the differentiation process. Levels of inflammatory markers such as resistin and IL-8 were increased as compared to the untreated cells. No significant changes in leptin were observed on treatment of adipose cells with rilpivirine alone and its levels were almost comparable to control. Levels of oxidative markers like superoxide dismutase, catalase, and glutathione were also decreased. Treatment with quercetin showed a decrease in the inflammatory status and an increase in the oxidative status of adipose cells, thereby exhibiting its anti-inflammatory and anti-oxidative properties. However, further assessment of lipid metabolism and adipose tissue function in patients administered with rilpivirine-based regimes is advisable considering that totally neutral effects of rilpivirine on lipid homeostasis cannot be anticipated from the current study in vitro. It is concluded that rilpivirine causes an anti-adipogenic and pro-inflammatory response pattern but only at high concentrations, whereas quercetin has been observed to decrease inflammation and restore the levels of anti-oxidant enzymes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Bailey AC, Fisher M (2008) Current use of antiretroviral treatment. Br Med Bull 87(1):175–192

    Article  CAS  PubMed  Google Scholar 

  2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338(13):853–860

    Article  PubMed  Google Scholar 

  3. Montessori V, Press N, Harris M, Akagi L, Montaner J (2004) Adverse effects of antiretroviral therapy for HIV infection. Can Med Assoc J 170(2):229–238

    Google Scholar 

  4. Slaven EM, Lopez F, Weintraub SL, Mena JC, Mallon WK (2003) The AIDS patient with abdominal pain: a new challenge for the emergency physician. Emerg Med Clin North Am 21(4):987–1015

    Article  PubMed  Google Scholar 

  5. Rasmussen LD, Kessel L, Molander LD, Pedersen C, Gerstoft J, Kronborg G, Obel N (2011) Risk of cataract surgery in HIV-infected individuals: a Danish nationwide population-based cohort study. Clin Infect Dis 53(11):1156–1163

    Article  PubMed  Google Scholar 

  6. Liu B, Zhang L, Guo R, Su J, Li L, Si Y (2012) Anti-infective treatment in HIV-infected patients during perioperative period. AIDS Res Therapy 9:36

    Article  CAS  Google Scholar 

  7. Grulich AE, Van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370(9581):59–67

    Article  PubMed  Google Scholar 

  8. World Health Organization (2003). Nutrient requirements for people living with HIV/AIDS: a report of a technical consultation’, WHO Technical Consultation on Nutrient Requirements for People living with HIV/AIDS, pp. 13–15. https://www.who.int/nutrition/publications/Content_nutrient_requirements.pdf

  9. World Health Organization [WHO] (1989) In vitro screening of traditional medicines for anti-HIV activity: memorandum from a WHO meeting. Bull World Health Organization 67:613–618

    Google Scholar 

  10. World Health Organization [WHO] (1989b). Report of a WHO informal consultation on traditional medicine and AIDS: in vitro screening for anti-HIV activity, Geneva, 6–8 February 1989. Geneva: World Health Organization.

  11. Vermani K, Garg S (2002) Herbal medicines for sexually transmitted diseases and AIDS. J Ethnopharmacol 80(1):49–66

    Article  PubMed  Google Scholar 

  12. Short RV (2006) New ways of preventing HIV infection: thinking simply, simply thinking. Phil Trans R Soc Lond 361(1469):811–820

    Article  CAS  Google Scholar 

  13. Abbot NC, Ernst E (1997) Patients′ opinions about complementary medicine. Complement Med Res 4(3):164–168

    Article  Google Scholar 

  14. Fairfield KM, Eisenberg DM, Davis RB, Libman H, Phillips RS (1998) Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Internal Med 158(20):2257–2264

    Article  CAS  Google Scholar 

  15. Sparber A, Wootton JC, Bauer L, Curt G, Eisenberg D, Levin T, Steinberg SM (2000) Use of complementary medicine by adult patients participating in HIV/AIDS clinical trials. J Altern Complement Med 6(5):415–422

    Article  CAS  PubMed  Google Scholar 

  16. Gore-Felton C, Vosvick M, Power R, Koopman C, Ashton E, Bachmann MH, Israelski D, Spiegel D (2003) Alternative therapies: a common practice among men and women living with HIV. J Assoc Nurses AIDS Care 14(3):17–27

    Article  PubMed  Google Scholar 

  17. Standish LJ, Greene KB, Bain S, Reeves C, Sanders F, Wines RCM, Turet P, Kim JG, Calabrese C (2001) Alternative medicine use in HIV-positive men and women: demographics, utilization patterns and health status. AIDS Care 13(2):197–208

    Article  CAS  PubMed  Google Scholar 

  18. Duggan J, Peterson WS, Schutz M, Khuder S, Charkraborty J (2001) Use of complementary and alternative therapies in HIV-infected patients. AIDS Patient Care STDs 15(3):159–167

    Article  CAS  PubMed  Google Scholar 

  19. Schrijvers R, Desimmie BA, Debyser Z (2011) Rilpivirine: a step forward in tailored HIV treatment. Lancet 378(9787):201–203

    Article  PubMed  Google Scholar 

  20. Sultana B, Anwar F (2008) Flavonols (kaempeferol, quercetin, myricetin) contents of selected fruits, vegetables and medicinal plants. Food Chem 108(3):879–884

    Article  CAS  PubMed  Google Scholar 

  21. Salvamani S, Gunasekaran B, Shaharuddin AN, Ahmad SA, Shukor Y (2014) Antiartherosclerotic effects of plant flavonoids. BioMed Res Intl, Article I.D, p 480258

    Google Scholar 

  22. Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP (1998) Effectiveness of potent antiretroviral therapy on time to aids and death in men with known HIV infection duration. JAMA 280(17):1497–1503

    Article  CAS  PubMed  Google Scholar 

  23. Bacchetti P, Gripshover B, Grunfeld C et al (2005) Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 40(2):121–131

    Article  PubMed  Google Scholar 

  24. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K (2011) Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 378(9787):229–237

    Article  CAS  PubMed  Google Scholar 

  25. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K (2011) Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 378(9787):238–246

    Article  CAS  PubMed  Google Scholar 

  26. Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guyer B, Williams S, Chuck S, Vanveggel S, Deckx H, Stevens M (2013) Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE studies. HIV Clinical Trials 14(3):81–91

    Article  CAS  PubMed  Google Scholar 

  27. Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K (2012) Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses 28(5):437–446

    Article  CAS  PubMed  Google Scholar 

  28. Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, Graells ML, Gutiérrez F (2007) Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients. Clin Ther 29(7):1448–1455

    Article  PubMed  Google Scholar 

  29. Mandas A, Iorio EL, Congiu MG, CinziaBalestrieri C, Mereu A, Cau D, Dessì S, Nicoletta Curreli N (2009) Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy. J Biomed Biotechnol. https://doi.org/10.1155/2009/749575

    Article  PubMed  PubMed Central  Google Scholar 

  30. Deavall DG, Martin EA, Horner JM, Roberts R (2012) Drug-induced oxidative stress and toxicity. J Toxicol. https://doi.org/10.1155/2012/645460

    Article  PubMed  PubMed Central  Google Scholar 

  31. de la Asunción JG, del Olmo ML, Sastre J, Millán A, Pellín A, Pallardó FV, Viña J (1998) AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Investig 102(1):4–9

    Article  PubMed  Google Scholar 

  32. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman GR (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 27(8):902–908

    CAS  PubMed  Google Scholar 

  33. Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, Rebeiro P, Haas DW (2003) Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis 37(12):1711–1717

    Article  CAS  PubMed  Google Scholar 

  34. Lewis W (2003) Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antiviral Res 58(3):189–197

    Article  CAS  PubMed  Google Scholar 

  35. Cossarizza A, Moyle G (2004) Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 18(2):137–151

    Article  CAS  PubMed  Google Scholar 

  36. Day BJ, Lewis W (2004) Oxidative stress in NRTI-induced toxicity: evidence from clinical experience and experiments in vitro and in vivo. Cardiovasc Toxicol 4(3):207–216

    Article  CAS  PubMed  Google Scholar 

  37. Tang AM, Lanzillotti J, Hendricks K, Gerrior J, Ghosh M, Woods M, Wanke C (2005) Micronutrients: current issues for HIV care providers. AIDS 19(9):847–861

    Article  PubMed  Google Scholar 

  38. Drain PK, Kupka R, Mugusi F, Fawzi WW (2007) Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy’. Am J Clin Nutr 85(2):333–345

    Article  CAS  PubMed  Google Scholar 

  39. Groot DH (1994) Reactive oxygen species in tissue injury. Hepatogastroenterology 41(4):328–332

    PubMed  Google Scholar 

  40. Grace PA (1994) Ischaemia-reperfusion injury. Br J Surg 81(5):637–647

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Forensic and Applied Sciences, University of Central Lancashire, Preston, Lancashire, PR1 2HE, England, UK

    Shalini Behl & Jaipaul Singh

  2. Department of Pharmacology, United Arab Emirates University, Al Ain, United Arab Emirates

    Abdu Adem

  3. School of Life Sciences, Manipal Academy of Higher Education, Dubai, United Arab Emirates

    Arif Hussain

Authors
  1. Shalini Behl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdu Adem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arif Hussain
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jaipaul Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shalini Behl.

Ethics declarations

Conflict of interest

The authors declare no conflict of interests with respect to the present paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Behl, S., Adem, A., Hussain, A. et al. Effect of the anti-retroviral drug, rilpivirine, on human subcutaneous adipose cells and its nutritional management using quercetin. Mol Cell Biochem 471, 1–13 (2020). https://doi.org/10.1007/s11010-020-03744-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-020-03744-4

Keywords

Search

Navigation